EXHIBIT 10.56

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4) and
240.24b-2(b)(1)
IL-13 AGREEMENT
BY AND BETWEEN THE UNDERSIGNED :
IDM Immuno-Designed Molecules, a French société anonyme with a capital of 1 164
736.90 Euros having its principal place of business at 172 rue de Charonne,
Paris (75011) and registered at the Paris Register of Trade and Companies under
B 382 632 263 represented by Jean-Loup Romet-Lemonne, President, and Bernard
Brigonnet, General Director (hereinafter, “IDM”).
AND:
SANOFI-SYNTHELABO, a French société anonyme with a capital of 1 462 883 492
Euros having its principal place of business at 174, avenue de France, 75013
Paris, and registered at the Paris Register of Trade and Companies under B 395
030 844, represented by Jean-Claude Leroy, Senior Vice President Strategy and
Business Development and José Ferrer, Director Operations Legal Affairs
(hereinafter “SANOFI-SYNTHELABO”);
When used in this IL-13 agreement, capitalized terms have the meaning assigned
in Article 1 of this IL-13 agreement.
RECITALS :
Whereas IDM is a biotechnology company incorporated in 1993 that, since
inception, has developed a Know-how and expertise in the field of immunotherapy,
and particularly in the field of ex vivo cancer treatments in humans.
Whereas SANOFI-SYNTHELABO is a pharmaceutical company that develops,
manufactures and/or markets pharmaceutical products in the field of human health
on a worldwide basis. In the course of its R&D, it discovered and developed a
cytokine known as Interleukin 13 (« IL-13 »), for which it applied for and
obtained patents and developed Know-how.
Whereas, on July 13, 1999, SANOFI-SYNTHELABO and IDM entered into an agreement
(« the 1999 Agreement ») defining the terms and conditions under which
SANOFI-SYNTHELABO granted IDM a non-exclusive license to its IL-13 Intellectual
Property rights relative to the IL-13 cytokine, in return for SANOFI-

1

--------------------------------------------------------------------------------

 

SYNTHELABO’s taking a stake in the capital of IDM, along with an exclusive
marketing option for SANOFI-SYNTHELABO in the event developments carried out by
IDM are successful.
Whereas in application of the 1999 Agreement, the Parties executed on July 13,
1999 a contribution agreement (the « Contribution Agreement ») pursuant to which
SANOFI-SYNTHELABO contributed to IDM the following assets, valued at [...***...]
:

  (a)   full ownership [...***...] of IL-13 (non GMP) equivalent to a minimum of
[...***...] biological activity units of IL-13.     (b)   a non-exclusive right
to use the IL-13 Intellectual Property for the purpose of using, implementing,
developing, exploiting in all forms and by all means the IL-13 Intellectual
Property and, in particular, IL-13 products resulting from that Intellectual
Property, exclusively in the field of ex vivo therapy for the purpose of
carrying out Phase I and Phase II Studies in one or more Development Programs
involving an IL-13 Product and for the marketing of IL-13 Research Kits during
Phase I and II Studies.     (c)   a non-exclusive right to use, under certain
conditions, the IL-13 Intellectual Property for the purpose of using,
implementing, developing, exploiting in all forms and by all means the IL-13
Intellectual Property and, in particular, IL-13 products resulting from that
Intellectual Property exclusively in the field of ex vivo therapy in order to
carry out Phase III Studies in one or more Development Programs involving an
IL-13 Product.     (d)   a non-exclusive right to use, under certain conditions,
the IL-13 Intellectual Property for the purpose of using, implementing,
developing, exploiting in all forms and by all means the IL-13 Intellectual
Property and, in particular, IL-13 products resulting from that Intellectual
Property exclusively in the field of ex vivo therapy for the marketing of Final
IL-13 Products.

Whereas IDM and SANOFI-SYNTHELABO having expressed their desire to strengthen
their collaboration in the field of ex vivo cellular therapies for humans
executed on July 20, 2001 a memorandum of agreement pursuant to which
SANOFI-SYNTHELABO has a priority right, on the terms and conditions defined in
this memorandum of agreement, to all IDM Development Programs in the area of ex
vivo cellular therapy in humans, whether or not they require IL-13 (hereinafter,
« the 2001 Agreement »).
The Parties further wished to revise certain provisions of the 1999 Agreement
and agreed, in Article 8 of the 2001 Agreement, on general principles that are
to apply to the amendment to the 1999 Agreement.

         
 
  *   Confidential Treatment Requested
under 17 C.F.R. §§ 200.80(b)(4) and
 
      240.24b-2(b)(1)

2

--------------------------------------------------------------------------------

 

In view of the complexity created by the coexistence of these two agreements,
the 1999 Agreement and the 2001 Agreement, the Parties hereby agree to amend the
1999 Agreement and to make more explicit certain provisions of this Agreement.
This IL-13 Agreement constitutes the amendment to the 1999 Agreement specified
in Article VIII of the 2001 Agreement.
NOW, THEREFORE, THE PARTIES MUTUALLY AGREE AS FOLLOWS:
ARTICLE 1 — DEFINITIONS

1.1.   ABSA shall mean 7.283 class B shares with attached B-share subscription
warrants issued by IDM to SANOFI-SYNTHELABO and fully paid up through the
Contribution, at the Extraordinary Shareholders’ Meeting of IDM held on
January 7, 2000.   1.2.   1999 Agreement shall mean the memorandum of agreement
executed by the Parties on July 13, 1999.   1.3.   IL-13 Agreement shall mean
this Agreement, including all its Attachments.   1.4.   2001 Agreement shall
mean the memorandum of agreement executed by the Parties on July 20, 2001.  
1.5.   Affiliate shall mean any entity controlled by a Party, controlling that
Party or under the same control as that Party, in each case either directly or
indirectly. For the needs of this definition, “control” means the holding
(directly or indirectly through an Affiliate) of more than 50% of the capital or
voting rights of a company. The status of an Affiliate is determined as of the
date on which this definition needs to be used.   1.6.   MA (AMM) or Marketing
Approval shall mean the official approval to market a Final IL-13 Product
granted by the relevant health authority in each country in the Territory or
each group of countries in the Territory.   1.7.   Reference MA shall mean any
MA granted :

  –   for the territory of the United States of America ; or     –   for the
territory of Japan ; or     –   for the territories of at least three of the
following five countries : France, Germany, the United Kingdom, Italy, or Spain
; or

3

--------------------------------------------------------------------------------

 

  –   issued by the European Drug Agency (EMEA) for the marketing of any of the
Final IL-13 Products on the territory of countries that recognize the competence
of that agency.

1.8.   Contributions shall mean contributions in kind entailing full title and
ownership (as recalled in the recitals of this agreement) made by SANOFI
-SYNTHELABO under the 1999 Agreement, and more specifically, the Contributions
Agreement.   1.9.   Amendment to the IL-13 License Agreement shall mean the
amendment to the IL-13 License Agreement to be executed by the Parties, on terms
and conditions specified in Article 6.3.2, and a model of which is set forth in
Attachment 6.3.2.   1.10.   IL-13 Patents shall mean patent applications and
patents belonging to SANOFI-SYNTHELABO, a descriptive list of which is given in
Attachment 1.10, including all divisions, continuations in part and extensions
of said patents, certificates of addition, certificates of utility and
supplementary certificates of protection.   1.11.   BSA 1 warrants shall mean
7,283 B-share subscription warrants attached to the ABSA granting the right to
subscribe 161,860 (or 8,093 multiplied by 20 following the 20 split approved by
the Extraordinary Shareholders’ Meeting held on June 21, 2001) new IDM B-shares
by exercise of Option 1 for a total price of [...***...].   1.12.   BSA 2
warrants shall mean 7,283 B-share subscription warrants attached to the ABSA
granting the right to subscribe 242,800 (or 12,140 multiplied by 20 following
the 20 split approved by the Extraordinary Shareholders’ Meeting held on
June 21, 2001) new IDM B-shares by exercise exercise of Option 2 for a total
price of [...***...].   1.13.   Change of Control of IDM shall mean the transfer
of shares and/or other financial instruments in any form whatsoever, which
effect is to cause a Third Party who was not an IDM shareholder on the effective
date of the 1999 Agreement, to hold directly or indirectly more than 50% of the
capital and/or voting rights of IDM. Attachment 1.13 contains a list of IDM
shareholders as of the effective date of the 1999 Agreement.   1.14.   IL-13 Net
Sales shall mean net sales before taxes made by IDM and/or by any authorized IDM
licensee (except SANOFI-SYNTHELABO) in connection with the Final IL-13 Products
and/or the IL-13 Research Kits after deduction of discounts, reductions and
rebates granted to Third Parties, the cost of Final IL-13 Products or IL-13
Research Kits returned, commissions paid, miscellaneous taxes paid on the sale
of Final IL-13 Products or IL-13 Research Kits, market access costs and custom
duties

         
 
  *   Confidential Treatment Requested
under 17 C.F.R. §§ 200.80(b)(4) and
 
      240.24b-2(b)(1)

4

--------------------------------------------------------------------------------

 

    as well as transport and insurance costs relative to these sales, except
Final IL-13 Products or IL-13 Research Kits used by IDM or by any IDM
sublicensee for internal purposes — training, development, studies, research —
within the context of its (their) activities.   1.15.   Executive Committee
shall mean the executive committee referred to in Article 4.1(a) of the 2001
Agreement.   1.16.   IL-13 License Agreement shall mean the license contact that
is to be executed by the Parties on the terms and conditions specified in
Article 6.2.2, a model of which is given in Annex 6.2.2.   1.17.   Not
applicable   1.18.   Effective Date shall mean the date the 2001 Agreement takes
effect.   1.19.   Implementation Date shall mean January 7, 2000.   1.20.  
Phase I Study (Studies) shall mean, within the context of a given IL-13
Development Program, all tolerance studies of an IL-13 Product as well as any
pharmacodynamic study relative to said IL-13 Product conducted by IDM in treated
patients.   1.21.   Phase II Study (Studies) shall mean, within the context of a
given IL-13 Development Program, all studies conducted by IDM to demonstrate
clinical activity of the IL-13 Product in treated patients.   1.22.   Phase III
Study (Studies) shall mean, within the context of a given IL-13 Development
Program, all studies conducted by IDM to confirm the efficacy and evaluate the
long-term tolerance of an IL-13 Product in order to obtain Marketing Approval
for the Final IL-13 Product in the Countries of the Territory.   1.23.  
Exercise of Option 1 shall mean the occurrence of one of the events referred to
in Article 6.2.2.   1.24.   Exercise of Option 2 shall mean the obtaining of a
Reference MA.   1.25.   IL-13 shall mean the protein with human cytokinic
activity, cloned and discovered by SANOFI-SYNTHELABO as more precisely described
in Annex 1.25.   1.26.   IL-13 Research Kits shall mean the IL-13 Product or
Products, in any form whatsoever, (i) developed in whole or in part by IDM
and/or any authorized IDM sublicensee within the scope of this IL-13 Agreement,
and which manufacture and/or marketing and/or utilization is covered by one or
more

5

--------------------------------------------------------------------------------

 

    IL-13 Patents and (ii) marketed for one or more of the following uses (a)
for research purposes only without therapeutic use, and/or (b) for clinical
trial purposes and without therapeutic use except as it results naturally from
such clinical trials.   1.27.   Development Offer shall mean the offer that IDM
must make to SANOFI-SYNTHELABO in application of Article III of the 2001
Agreement in order to allow the latter to exercise, or not, its Development
Option right.   1.28.   Development Option shall mean the irrevocable option
enjoyed by SANOFI-SYNTHELABO pursuant to Article III of the 2001 Agreement
granting it, if it exercises the option with regard to a given Development
Program, exclusive rights to benefit from the exploitation of the results of the
corresponding Development Program, in return for its financing of the costs and
expenses relative to said Development Program.   1.29.   Exclusive License
Option shall mean the irrevocable option enjoyed by SANOFI-SYNTHELABO pursuant
to Article VI of the 2001 Agreement.   1.30   IDM Shareholders’ Agreement shall
mean the shareholders’ agreement among IDM’s shareholders dated December 29,
1996 and amended on August 31, 1998, October 29, 1998, January 7, 2000 and
October 6, 2000, and, if applicable, any subsequent additional amendment.  
1.31.   Parties shall mean SANOFI-SYNTHELABO and IDM collectively (each of the
Parties being individually designated as a “Party”).   1.32.   Improvements
shall mean any improvements and upgrades made to the IL-13 Intellectual
Property, whether or not they are covered by patents or certificates of utility
or any other intellectual property title.   1.33.   IL-13 Product shall mean any
Product, as defined in Article 1.18 of the 2001 Agreement, that includes a
dendritic cell obtained using IL-13.   1.34.   Final IL-13 Product shall mean
any Final Product, as defined in Article 1.19 of the 2001 Agreement, that
pertains to an IL-13 Product.   1.35.   Development Program shall mean, for a
given Product in a specified therapeutic indication, all pre-clinical studies
and clinical studies carried out or to be carried out by IDM and necessary for
the preparation of MA applications in the Territory. IL-13 Development Program
shall mean any Development Program pursuant to this definition that pertains to
an IL-13 Product. For information, Annex 1.35 contains a list of the IL-13
Development Programs currently in progress. The term SANOFI-SYNTHELABO IL-13
Development Program shall mean an IL-13 Development Program as to which
SANOFI-SYNTHELABO has exercised

6

--------------------------------------------------------------------------------

 

    its Development Option right per Article III of the 2001 Agreement and that
has not been interrupted in accordance with the provisions of the 2001
Agreement.   1.36.   IL-13 Intellectual Property shall mean, collectively, the
IL-13 Patents, the IL-13 Know-How, as well as any intellectual property right
that SANOFI-SYNTHELABO might have, either before or after the date of signature
of the 1999 Agreement, and/or that is freely available to it and that is
necessary (i) for the marketing of the IL-13 Research Kits or (ii) for the
implementation of the IL-13 Development Programs and (iii) the marketing of the
Final IL-13 Products.   1.37.   IL-13 Know-How shall mean all knowledge,
experience and experimentation, information and expert reports relative to IL-13
and to the inventions claimed in the IL-13 Patents, that SANOFI-SYNTHELABO
developed, as well as those to which it had access, provided they were freely
available to it and provided they existed in any physically transmissible form
on the execution date of the 1999 Agreement .   1.38.   Territory shall mean the
entire world.   1.39.   Third Party shall mean any individual or any legal
entity except the Parties and their Affiliates.

ARTICLE 2 — PURPOSE
The purpose of this IL-13 Agreement is:

  (a)   to amend the conditions under which IDM will be supplied with IL-13;    
(b)   to specify the terms of the IL-13 Intellectual Property license granted by
SANOFI-SYNTHELABO to IDM for (i) marketing IL-13 Research Kits,
(ii) implementation of IL-13 Development Programs and (iii) marketing Final
IL-13 Products.

This IL-13 Agreement cancels and replaces, as of the Effective Date, the
provisions of the 1999 Agreement with the exception of the Contributions
Contract.
ARTICLE 3 — IL-13 SUPPLY
Further to the decision made by SANOFI-SYNTHELABO to stop supplying IL-13 to
IDM, SANOFI-SYNTHELABO hereby grants IDM, which accepts it, a free non-exclusive
license to the IL-13 Intellectual Property and Improvements, to the

7

--------------------------------------------------------------------------------

 

extent they are necessary for the manufacturing of IL-13, in order to enable IDM
to manufacture, for its own exclusive use, the required amounts of IL-13 to
carry out IL-13 Development Programs and marketing of Final IL-13 Products.
This license includes the right for IDM to sub-license the IL-13 Intellectual
Property and Improvements, to the extent the latter are necessary for the
manufacturing of IL-13, to one (or more) Third Parties, provided that (i) the
Third Party or Parties are pre-approved by SANOFI-SYNTHELABO, which may not
refuse its consent without a serious reason, and (ii) IDM concludes with the
Third Party or Parties a license contract which terms and conditions are
consistent with the provisions of this Article 3.
ARTICLE 4 — NON-EXCLUSIVE NATURE OF GRANTED RIGHTS
IDM declares that it knows and accepts the fact that the rights granted by
SANOFI-SYNTHELABO to IDM to the IL-13 Intellectual Property under this IL-13
Agreement are not exclusive.
ARTICLE 5 — CANCELLATION OF THE EXCLUSIVE MARKETING OPTION
The exclusive marketing option right enjoyed by SANOFI-SYNTHELABO under
Article 8.2.2. of the 1999 Agreement is hereby cancelled.
ARTICLE 6 —IL-13 LICENSE

6.1.   Marketing of IL-13 Research Kits       IDM may market IL-13 Research Kits
during the life of this IL-13 Agreement, of the IL-13 License Agreement and of
the Amendment to the IL-13 License Agreement. In this case, IDM shall pay
SANOFI-SYNTHELABO a royalty equal to [...***...] of Net Sales made by IDM under
such marketing.       It is specified that [...***...] of the above referenced
royalty is in consideration of the license granted to the IL-13 Patents and
[...***...] is in consideration of the license granted for the IL-13 Knowhow,
this royalty being only due during the life of this IL-13 Agreement.       The
payment by IDM of the amounts due under this Article 6.1 shall be made twice a
year, on the last working day of the months of February and August of each year,
by bank transfer to the account specified by SANOFI-SYNTHELABO. Each payment
shall include a statement of IL-13

         
 
  *   Confidential Treatment Requested
under 17 C.F.R. §§ 200.80(b)(4) and
 
      240.24b-2(b)(1)

8

--------------------------------------------------------------------------------

 

    Research Kits sales made during the corresponding six calendar months that
makes it possible to identify the amounts payable.       IDM shall have a
special accounting procedure, with the corresponding substantiating documents,
covering all elements necessary for calculating the amounts owed to
SANOFI-SYNTHELABO pursuant to the above provisions. SANOFI-SYNTHELABO may cause
IDM’s books to be verified, at its simple request made with sufficient advance
notice, by an independent expert jointly chosen by the Parties and, absent an
agreement within fifteen (15) days of the date on which SANOFI-SYNTHELABO has
requested the audit, by the Presiding Judge of the Lower Court of Paris on the
petition of the first acting Party. The expert shall use its best efforts to
notify his findings within a period of thirty (30) days after referral. The
findings of this expert shall be final and without recourse. The expert’s fees
and costs will be covered by SANOFI-SYNTHELABO except if the total amount owed
to SANOFI-SYNTHELABO is more than five per cent (5%) greater than the amount
reported by IDM, in which case these costs and fees shall be covered by IDM.  
6.2.   Implementation of IL-13 Development Programs — Exercise of BSA 1 warrants
  6.2.1.   Phase I and II studies       Except for SANOFI-SYNTHELABO IL-13
Development Programs that are governed by the 2001 Agreement, IDM agrees to
implement and pursue the Phase I and II Studies of the IL-13 Development
Programs at its sole expense. IDM will use its best efforts to complete the
Phase I and II Studies at the earliest possible time compatible with applicable
legal and regulatory requirements.       IDM will provide SANOFI-SYNTHELABO with
a summary report of the results of the Phase II Studies carried out on one or
more IL-13 Products within six (6) months following completion of these Phase II
Studies.   6.2.2.   Exercise of the BSA 1 warrants       The occurrence of one
of the following events shall be deemed to be equivalent to Exercise of Option 1
as specified in the provisions for the exercise of BSA 1s described in Annex 7:
      Events:

  (a)   The Executive Committee decides to undertake a Phase III Study on an
IL-13 Product in application of Article 5.4.a) (ii) of the 2001 Agreement. In
that event, Option 1 shall be deemed to have been

9

--------------------------------------------------------------------------------

 

      exercised on the date of signature of the joint report setting forth the
decision of the Executive Committee to start a Phase III Study; or

  (b)   IDM decides to undertake a Phase III Study on an IL-13 Product that is
not covered by a SANOFI-SYNTHELABO IL-13 Development Program. In that event, IDM
shall notify SANOFI-SYNTHELABO of its decision to start Phase III Studies by
registered mail with return receipt sent within six (6) months of the completion
of the Phase II Studies carried out on such IL-13 Product. Option 1 shall be
deemed to have been exercised on the date of the first presentation to
SANOFI-SYNTHELABO of such registered mail with return receipt.

    Within thirty (30) days from the occurrence of one of the above events, the
Parties agree to enter into an IL-13 License Agreement pursuant to the model
contained in Annex 6.2.2., defining (i) the terms and conditions under which IDM
may use and exploit the IL-13 Intellectual Property to carry out Phase III
Studies on IL-13 Products and (ii) the terms and conditions of the payment for
the IL-13 Intellectual Property license thus granted by SANOFI-SYNTHELABO. The
IL-13 License Agreement shall take effect as of the Exercise date of Option 1.
On the date of execution of the IL-13 License Agreement, SANOFI-SYNTHELABO shall
submit to IDM an invoice for the amount specified in Article 4.1.1. of the IL-13
License Agreement, plus any applicable amount of value-added tax, as well as a
simplified subscription form requesting exercise of the BSA 1 warrants      
Within thirty (30) days of the signing of the IL-13 License Agreement, IDM shall
cause its Board of Directors to draw up a statement of account, to be certified
by its auditors, and the Board of Directors shall acknowledge issuance of the
shares resulting from the exercise of the BSA 1 warrants.   6.2.3.   Phase III
Studies

Except for SANOFI-SYNTHELABO IL-13 Development Programs that are governed by the
2001 Agreement:

  –   IDM agrees to carry out at its sole expense Phase III Studies of IL-13
Development Programs and to use its best efforts to complete such Phase III
Studies at the earliest possible time compatible with applicable legal and
regulatory requirements.     –   IDM shall provide SANOFI-SYNTHELABO with
semi-annual progress reports on Phase III Studies and shall keep
SANOFI-SYNTHELABO informed as soon as possible about any problem that could have
a significant negative effect on said Phase III Studies.

10

--------------------------------------------------------------------------------

 

  –   Representatives of IDM and SANOFI-SYNTHELABO shall meet, at the request of
either Party, to discuss the contents of semi-annual progress reports on Phase
III Studies as provided by IDM. During these meetings, IDM will provide any
supplementary information that SANOFI-SYNTHELABO might reasonably request about
the results of Phase III Studies, to the extent this additional information is
available on the date of the request by SANOFI-SYNTHELABO, and does not require
any additional research or investigations beyond those conducted by IDM.     –  
IDM will provide SANOFI-SYNTHELABO with a summary report on Phase III Studies
carried out on one or more of the IL-13 Products within sixty (60) days
following the completion of these Phase III Studies.

6.3.   Marketing of Final IL-13 Products — Exercise of BSA 2 warrants   6.3.1.  
IDM’s decision to market Final IL-13 Products       Except for SANOFI-SYNTHELABO
IL-13 Development Programs that are governed by article V of the 2001 Agreement
:

  (a)   IDM shall notify SANOFI-SYNTHELABO of its decision to market a Final
IL-13 Product by registered mail with return receipt sent within six (6) months
following completion of the Phase III Studies on the corresponding IL-13
Product;     (b)   IDM agrees to file MA applications as soon as possible for
the corresponding IL-13 Product.

6.3.2.   Exercise of BSA 2 warrants       The obtaining by SANOFI-SYNTHELABO,
within the context of a SANOFI-SYNTHELABO IL-13 Development Program governed by
the 2001 Agreement, or by IDM under Article 6.3.1(b) above, of a Reference MA
shall be deemed as equivalent to the Exercise of Option 2 as specified in the
terms and conditions for the exercise of the BSA 2 warrants described in Annex
7. Within thirty (30) days following the obtaining of such Reference MA, the
Parties agree to conclude an Amendment to the IL-13 License Agreement pursuant
to the model set forth in Annex 6.3.2 defining the conditions under which IDM
can use and exploit the IL-13 Intellectual Property to market any Final IL-13
Product and (ii) the terms and conditions of payment for the IL-13 Intellectual
Property license thus granted by SANOFI-SYNTHELABO.

11

--------------------------------------------------------------------------------

 

    On the date of execution of the Amendment to the IL-13 License Agreement,
SANOFI-SYNTHELABO shall submit an invoice to IDM for the amount specified in
Article 4.1.2. of the IL-13 License Agreement as amended by the Amendment to the
IL-13 License Agreement, plus any applicable amount for value-added taxes, in
addition to a simplified subscription form requesting exercise of the BSA 2
warrants.       Within thirty (30) days following the signature of the Amendment
to the IL-13 License Agreement, IDM shall cause its Board of Directors to draw
up a statement of account, certified by its auditors, and the Board of Directors
shall acknowledge issuance of the shares resulting from the exercise of the BSA
2 warrants.

ARTICLE 7 — OFFSET
By express agreement between the Parties, all amounts payable to
SANOFI-SYNTHELABO by IDM under the IL-13 License Agreement and the Amendment of
the IL-13 License Agreement, shall be owed by IDM only provided the latter can
pay by offset against any amount owed to it by SANOFI-SYNTHELABO for the payment
in full of the shares subscribed through the exercise of BSA 1 and/or BSA 2
warrants.
Lack of exercise of BSA1 and/or BSA2 warrants at the latest on their exercise
date as indicated in the early exercise provisions in Annex 7, shall be deemed
equivalent to SANOFI-SYNTHELABO renouncing to request any payment by IDM of any
of the fixed amounts indicated in such articles.
ARTICLE 8 — EARLY EXERCISE OF BSA 1 AND BSA 2 WARRANTS
In the event of a transfer by IDM of all its assets to an authorized Third Party
transferee, on the terms and conditions specified in Article 15.2(c), or in the
event of a change of control of IDM, Option 1 and/or Option 2 shall be deemed
exercised in advance, even though conditions for the exercise of these Options
have not been met, through application of the following provisions :

8.1.   Transfer by IDM of all its assets to a Third Party transferee.      
Transfer to a Third Party transferee shall be deemed equivalent to the Exercise
of Option 1 and/or Option 2.   8.2.   Change of control of IDM       In the
event IDM shares are traded on a regulated market, SANOFI-SYNTHELABO shall
notify IDM within fifteen (15) days following the

12

--------------------------------------------------------------------------------

 

    official filing of the operation likely to entail a Change of Control of IDM
of its decision to proceed with an early exercise its BSA 1 and/or BSA 2
warrants.       In the event IDM shares are not traded on a regulated market,
SANOFI-SYNTHELABO shall notify IDM of its decision to exercise its BSA 1 and/or
BSA 2 warrants no more than ten (10) days prior to implementation of the Change
of Control of IDM, of which SANOFI-SYNTHELABO shall have been notified, either
by application of the IDM shareholders’ agreement or by prior notification by
IDM sent to SANOFI-SYNTHELABO at least twenty (20) days prior to the
implementation of the Change of Control of IDM, in the event the IDM
shareholders’ agreement is null and void.       Receipt by IDM of the notice of
early exercise by SANOFI-SYNTHELABO of its BSA 1 and/or BSA 2 warrants shall be
deemed equivalent to the Exercise of Option 1 and/or of Option 2.       In the
event of a decision by SANOFI-SYNTHELABO not to exercise its BSA 1 and/or BSA 2
warrants early, or absent a reply from SANOFI-SYNTHELABO within fifteen
(15) days of ten (10) days as specified above, the provisions of this IL-13
Agreement shall continue to apply between the Parties.   8.3.   Exercise of BSA
1 and/or BSA 2 warrants       In the instances specified in Articles 8.1 and 8.2
above, exercise of BSA 1 and/or BSA 2 warrants shall occur on the date of the
Transfer to the Third-Party transferee in the case covered by Article 8.1 and,
in the case covered by Article 8.2, on the date set by IDM within a period of
seven (7) days following the date of receipt by IDM of the notice specified in
Article 8.2.       On the date of exercise of the BSA 1 and/or BSA 2 warrants:

  –   the Parties shall enter into the IL-13 License Agreement and/or the
Amendment to the IL-13 License Agreement;     –   SANOFI-SYNTHELABO shall submit
an invoice to IDM for the amount of the fixed compensation specified in
Article 4.1.1 of the IL-13 License Agreement and/or the fixed compensation
specified in Article 4.1.2 of the IL-13 License Agreement as amended by the
Amendment to the IL-13 License Agreement, as well as a simplified subscription
form requesting the exercise of BSA 1 and/or BSA 2 warrants;     –   IDM shall
hold a meeting of the Board of Directors to draw up a

13

--------------------------------------------------------------------------------

 

      statement of account certified by its internal auditors, and the Board of
Directors shall acknowledge issuance of the shares resulting from the exercise
of BSA 1 and BSA 2 warrants.

ARTICLE 9 — RESPONSIBILITY — INSURANCE

9.1.   Without prejudice to the provisions of common law, IDM alone shall assume
any responsibility that might arise from the implementation of IL-13 Development
Programs, as well as from the exploitation of the results, vis-à-vis any Third
Party and on any basis whatsoever, including on the basis of civil liability, in
particular with respect to any damage that might result from the use (in
carrying out the Phase I and II Studies) of IL-13 supplied by SANOFI-SYNTHELABO
and not manufactured in accordance with “Good Manufacturing Practices”.      
IDM alone shall also assume any liability that might arise (i) from any fault
committed by it or by any IDM Affiliate or sub-licensee within the context of
the implementation of this IL-13 Agreement, as well as (ii) for any failure on
its part or on the part of any IDM Affiliate or sub-licensee to perform its
obligations pursuant to said IL-13 Agreement.       IDM shall also hold
SANOFI-SYNTHELABO harmless with regard to any harmful consequences that might
arise for SANOFI-SYNTHELABO from any action brought against SANOFI-SYNTHELABO by
a Third Party based on damage of any kind whatsoever resulting from the
circumstances indicated above.       IDM warrants that it has taken out, at its
sole expense, the necessary insurance coverage on terms and conditions
consistent with the practices in the pharmaceutical industry, in order to
sufficiently cover any risks that might result from the implementation of the
IL-13 Development Programs and/or the marketing of the IL-13 Research Kits
and/or the Final IL-13 Products. It shall provide evidence of such coverage at
the request of SANOFI-SYNTHELABO.   9.2.   Without prejudice to the provisions
of common law, SANOFI-SYNTHELABO alone shall assume the liability that could
result (i) from any fault committed by it or by any SANOFI-SYNTHELABO Affiliate
or sub-licensee within the context of the implementation of this IL-13
Agreement, (ii) from any failure by it or by any SANOFI-SYNTHELABO Affiliate or
sub-licensee to meet its obligations under said Agreement, as well as (iii) from
its supply to IDM of IL-13 that is not up to contractual specifications.

14

--------------------------------------------------------------------------------

 

    Consequently, it guarantees IDM against all prejudicial consequences that
might arise for IDM from an action brought against it by a Third Party based on
damage of any kind whatsoever resulting from the circumstances identified above.
      SANOFI-SYNTHELABO guarantees that it has taken out the necessary insurance
at its sole expense, on terms and conditions consistent with the practices of
the pharmaceutical industry, in order to provide sufficient coverage of the
risks likely to arise from the quantities of supplied IL-13.   9.3.   The above
provisions do not apply to SANOFI-SYNTHELABO IL-13 Development Programs, which
are governed by the 2001 Agreement.

ARTICLE 10 — SANOFI-SYNTHELABO GUARANTEES
SANOFI-SYNTHELABO guarantees to IDM the existence of the IL-13 Patents and IL-13
Knowhow and the accuracy of its facts. In addition, SANOFI-SYNTHELABO declares
that it is sole owner of the IL-13 Patents and IL-13 Knowhow and guarantees that
it can freely and validly grant the rights to said IL-13 Patents and IL-13
Knowhow that it is granting under this IL-13 Agreement, the Contributions
Agreement, the IL-13 License Agreement and the Amendment to the IL-13 License
Agreement. The above guarantees are made subject to the statements included in
Annex 10, in particular as regards the existence on the territory of the United
States of patents filed by [...***...] SANOFI-SYNTHELABO agrees to keep the
IL-13 Patents in force in accordance with applicable legal and regulatory
provisions, in particular by carrying out, at the appropriate time, necessary
procedures and formalities, provided that, in the event of an extension of the
IL-13 Patents or corresponding supplementary protection certificates, IDM has
provided it with all necessary documents and signatures, when the MA of the
Final IL-13 Product is not in the name of SANOFI-SYNTHELABO. All costs
pertaining thereto shall be paid by SANOFI-SYNTHELABO.
ARTICLE 11 — IMPROVEMENTS MADE OR ACQUIRED BY SANOFI-SYNTHELABO

11.1.   SANOFI-SYNTHELABO shall retain sole and full title to all Improvements
that it makes or acquires.       In order to allow IDM to have IL-13
manufactured, SANOFI-SYNTHELABO shall transmit to IDM free of charge and as soon
as possible any improvement related to the manufacturing and production
processes and/or methods for IL-13 and IL-13 made pursuant to “Good

         
 
  *   Confidential Treatment Requested
under 17 C.F.R. §§ 200.80(b)(4) and
 
      240.24b-2(b)(1)

15

--------------------------------------------------------------------------------

 

    Manufacturing Practices” that it may have at its disposal during the life of
this IL-13 Agreement in a physically transmissible form, and to which it shall
have unencumbered access.       As regards Improvements other than those
specified in the preceding paragraph, in the event SANOFI-SYNTHELABO wishes to
make these Improvements available to any Third Party, it irrevocably agrees to
offer them to IDM on conditions, especially financial conditions, at least equal
to the most favorable conditions offered to any Third Party, during the life of
this IL-13 Agreement, of the IL-13 License Agreement and of the Amendment to the
IL-13 License Agreement.   11.2.   Use of the IL-13 Intellectual Property
specified in the Contributions Agreement and all rights granted by
SANOFI-SYNTHELABO to IDM under this IL-13 Agreement, the IL-13 License Agreement
and the Amendment to the IL-13 License Agreement shall fully extend to
Improvements transmitted pursuant to the provisions of Article 11.1 above, as
soon as they are known, and SANOFI-SYNTHELABO shall, on its own initiative and
at its own expense, carry out all necessary formalities and procedures to
guarantee the effective implementation of this provision. IDM agrees to
participate, if necessary, in this protection and, in particular, to sign all
necessary acts and documents.   11.3.   Subject to the provisions of
Article 11.1, it is expressly agreed by the Parties that the transfer of
Improvements by SANOFI-SYNTHELABO shall not entail any change to the financial
terms and conditions of the Contributions Agreement, the IL-13 License Agreement
and the Amendment to the IL-13 License Agreement.

ARTICLE 12 — IMPROVEMENTS MADE OR ACQUIRED BY IDM

12.1.   IDM shall retain sole and full title to all results, tangible or
intangible, patentable or non-patentable, patented or not patented, arising from
the IL-13 Development Programs or from any improvements to its own patents that
it may make or acquire.       SANOFI-SYNTHELABO unconditionally and irrevocably
agrees not to claim any right whatsoever to IDM’s research or inventions.      
It shall be the responsibility of IDM, if it so wishes, to carry out at its own
expense all necessary formalities and steps to ensure the protection of its
rights under applicable statutes, and SANOFI-SYNTHELABO agrees to participate if
necessary in this protection and, in particular, to sign all necessary acts and
documents.

16

--------------------------------------------------------------------------------

 

12.2.   The above provisions apply subject to any conflicting provisions of the
2001 Agreement.

ARTICLE 13 — TERRITORY
Rights granted by SANOFI-SYNTHELABO to IDM under this IL-13 Agreement are
granted for the Territory.
ARTICLE 14 — TERM — CANCELLATION

14.1.   This IL-13 Agreement shall take effect on the Effective Date. It shall
be automatically cancelled in the event one of the Parties cancels the 2001
Agreement in application of Article 10.2 of that Agreement, in which case the
1999 Agreement shall automatically resume all its effects.   14.2.   This IL-13
Agreement shall remain in effect for a period equal to that of the legal
protection attached to the IL-13 Patents. The effect of this IL-13 Agreement
shall cease, in each of the countries involved, on the expiration date of the
last IL-13 Patent relative to that country.   14.3.   SANOFI-SYNTHELABO may
cancel this IL-13 Agreement pursuant to a simple notice by registered mail with
return receipt given sixty (60) days in advance, in the following cases:

  (a)   Option 1 has not been validly exercised no later than five (5) years
following the Implementation Date;     (b)   or, after Option 1 has been
exercised, Option 2 is not validly exercised no later than ten (10) years from
the Implementation Date;     (c)   on the expiration date of a period of five
(5) years calculated as of the filing of the first application for a Reference
MA, if by that date such MA has not been obtained.

14.4.   This IL-13 Agreement may also be cancelled by IDM in the event of
non-exercise of Option 1 or Option 2 for any IL-13 Development Program, subject
to a prior notice of sixty (60) days from the expiration date of each of the
notification deadlines defined in Articles 6.2.2(b) and 6.3.1(a) above,
respectively.   14.5.   In the event of cancellation, all quantities of IL-13
held by IDM on the cancellation date, to the extent these quantities correspond
to those contributed to IDM under the Contributions Agreement, as well as all
documents of any kind provided by SANOFI-SYNTHELABO to IDM

17

--------------------------------------------------------------------------------

 

    pursuant to the provisions of the 1999 Agreement, the Contributions
Agreement, this IL-13 Agreement or the IL-13 License Agreement, shall be
returned by IDM to SANOFI-SYNTHELABO not later than by the expiration date of
the notice of cancellation, without any economic consideration payable by
SANOFI-SYNTHELABO.   14.6.   This IL-13 Agreement may not be cancelled by
SANOFI-SYNTHELABO in application of Article 14.3 or by IDM in application of
Article 14.4 as long as a SANOFI-SYNTHELABO IL-13 Development Program is in
effect.

ARTICLE 15 — ASSIGNMENT OF THE IL-13 AGREEMENT

15.1.   Assignment of the IL-13 Agreement by SANOFI-SYNTHELABO      
SANOFI-SYNTHELABO shall have the right to freely transfer the rights arising
globally from the IL-13 Patents, IL-13 Knowhow, this IL-13 Agreement, the
Contributions Agreement, the IL-13 License Agreement and the Amendment to the
IL-13 License Agreement (in any form whatsoever, and specifically in the form of
assignment, contribution, exchange, merger, etc.) and shall be released from any
obligation under said agreements as of the date of their transfer.       In the
event of the isolated transfer of these agreements, SANOFI-SYNTHELABO agrees to
advise IDM of such a transfer not less than fifteen (15) days prior to the date
set for such transfer, subject to any legal, regulation or contractual
non-disclosure obligation regarding this information that is incumbent upon
SANOFI-SYNTHELABO.       In the event of the transfer of this package as part of
a transfer by SANOFI-SYNTHELABO of all or part of its activities,
SANOFI-SYNTHELABO agrees to advise IDM of such transfer not less than fifteen
(15) days prior to the date of such transfer, subject to any legal, regulatory
or contractual non-disclosure obligation regarding this information that is
incumbent upon SANOFI-SYNTHELABO.       In both hypotheses contemplated above,
the agreement implementing the transfer shall expressly indicate that the
beneficiary of the transfer shall be bound by all obligations incumbent upon
SANOFI-SYNTHELABO under the IL-13 Agreement, the Contributions Agreement, the
IL-13 License Agreement and the Amendment to the IL-13 License Agreement.      
In the event the above-referenced transfer is made to a SANOFI-SYNTHELABO
Affiliate, SANOFI-SYNTHELABO agrees (i) jointly with the Affiliate that the
latter shall fulfill the obligations incumbent upon the Affiliate under the
IL-13 Agreement, the Contributions Agreement, the

18

--------------------------------------------------------------------------------

 

    IL-13 License Agreement and the Amendment to the IL-13 License Agreement and
(ii) in the event the transferee subsequently ceases to be one of its
Affiliates, to cause the rights and obligations to be re-transferred ahead of
time to itself or to another Affiliate.   15.2.   Assignment of the IL-13
Agreement by IDM       IDM recognizes that its rights under this IL-13
Agreement, the Contributions Agreement, the IL-13 License Agreement and the
Amendment to the IL-13 License Agreement, are strictly personal. On that basis,
and subject to the provisions set forth below, IDM agrees not to assign,
transfer or convey its rights to anyone, whether directly or indirectly, in
whole or in part, against payment or free of charge, without prior written
authorization from SANOFI-SYNTHELABO. IDM further agrees not to confer to any
Third Party any right of any kind whatsoever on the Contributions.       By way
of exception to the above provisions, IDM may:

  (a)   assign, transfer or transmit its rights and obligations arising from
this IL-13 Agreement, the Contributions Agreement, the IL-13 License Agreement
and the Amendment to the IL-13 License Agreement to any of its Affiliates,
subject to the following cumulative conditions: (i) that IDM agrees, in the
event the transferee were subsequently to cease to be an IDM Affiliate, to cause
the rights and obligations to be first re-transferred to IDM or to any other IDM
Affiliate, (ii) that IDM shall be the joint guarantor that this Affiliate shall
respect these rights and obligations and (iii) that IDM shall reiterate the
commitments made to SANOFI-SYNTHELABO in Article 4.1.2. of the IL-13 License
Agreement or Article 4.1.3. of the IL-13 License Agreement, in the event the
assignment of IDM’s rights were to take place while BSA 1 and/or BSA 2 warrants
cannot as yet be exercised.     (b)   transfer its rights and obligations under
this IL-13 Agreement, the Contributions Agreement, the IL-13 License Agreement
and the Amendment to the IL-13 License Agreement following a takeover of IDM by
another company or the dissolution of IDM through a merger of capital assets and
holdings pursuant to the provisions of Article 1844-5 of the French Civil Code.
    (c)   Transfer its rights and obligations under this IL-13 Agreement, the
Contributions Agreement, the IL-13 License Agreement and the Amendment to the
IL-13 License Agreement as a result of the assignment or contribution of all its
activities to an entity other than an Affiliate.

19

--------------------------------------------------------------------------------

 

ARTICLE 16 — DEFENSE OF THE IL-13 INTELLECTUAL PROPERTY
SANOFI-SYNTHELABO shall have the obligation, at its sole expense:

  (a)   to defend in all circumstances the IL-13 Intellectual Property covered
by this Agreement, specifically by carrying out, both as plaintiff and as
respondent, both in France and abroad, all actions permissible under the law for
the holder of the IL-13 Intellectual Property;     (b)   to inform IDM as soon
as possible of all actions (in which it is the plaintiff or the respondent),
both current or planned, as well as of any threat in fact or by law to the IL-13
Intellectual Property which it might have knowledge of and which could have a
significant effect on the exploitation of the IL-13 Intellectual Property;    
(c)   not to create any obstacle in fact or by law to the potential intervention
of IDM in a given proceeding, provided that this intervention does not
potentially harm significantly SANOFI-SYNTHELABO’s interests.

IDM shall have the obligation of informing SANOFI-SYNTHELABO, at its sole
expense, of any infringement by Third Parties of the rights to the IL-13
Intellectual Property of which it might have knowledge.
The Parties, recognizing that certain bodies of law, including French law, do
not permit the non-exclusive holder of intellectual rights to act alone in any
legal proceedings, consider as essential the obligation imposed on
SANOFI-SYNTHELABO under this Article 16.
SANOFI-SYNTHELABO is bound by the obligation arising from this Article 16 only
provided the costs incurred by it for compliance remain reasonable in terms of
the stakes and probabilities of success of the actions undertaken. Consequently,
if these costs seem unreasonable to SANOFI-SYNTHELABO, it is understood that the
Parties shall get together in order to examine, in good faith, any alternative
solution that could be suitable to the objectives sought by each of the Parties.
ARTICLE 17 — CONFIDENTIALITY

17.1.   The confidentiality agreement executed on May 23, 1997 remains in effect
as to all provisions not contrary to the stipulations of this IL-13 Agreement
and shall continue, by express agreement of the Parties, to be incumbent upon
them for the entire life of this IL-13 Agreement and for a period of ten
(10) years following its expiration.

20

--------------------------------------------------------------------------------

 

17.2.   Absent any legal, regulatory or judicial constraint, each Party agrees
not to disclose this IL-13 Agreement and/or its annexes, to engage in any
publicity and/or to issue any press release as to the execution and the content
of this IL-13 Agreement without prior authorization of the other Party, which
authorization may not be refused without just cause. In no event may the
provisions of this IL-13 Agreement be construed as prohibiting IDM from
providing information on the results relative to IL-13 Development Programs.

ARTICLE 18 — ANNEXES
The following Annexes to this IL-13 Agreement cannot be separated from such
IL-13 Agreement, of which they are an integral part.
However, in case of conflict, the stipulations of this IL-13 Agreement shall
prevail over the stipulations of the Annexes, and in particular, in the case of
the IL-13 License Agreement and the Amendment to the IL-13 License Agreement.
ARTICLE 19 — SAFEGUARD CLAUSE
In view of the complexity of the operations proposed by the Parties under this
IL-13 Agreement and the 2001 Agreement and their Annexes, the Parties recognize
that they cannot reasonably anticipate all difficulties that may arise from
their execution.
In the event such difficulties were to arise, the Parties agree to negotiate in
good faith all supplements and/or changes to this IL-13 Agreement or its Annexes
that would make it possible to resolve their difficulties in a manner consistent
with the common intent of the Parties.
ARTICLE 20 — NOTICES
All notices under this IL-13 Agreement shall be given by registered mail with
return receipt to the addresses indicated in the header or to any other address
that may be made known in advance to one or other Party.
ARTICLE 21 — APPLICABLE LAW — DISPUTES
This IL-13 Agreement is governed by French law, provided, however, that this
cannot be an obstacle to the application in each State of the provisions of
local law that might grant longer, more extensive or more vigorous protection
for the IL-13 Patents and/or to the IL-13 Knowhow.

21

--------------------------------------------------------------------------------

 

Any differences arising from this IL-13 Agreement or in connection with it shall
be permanently resolved in accordance with the Rules of Arbitration of the
International Chamber of Commerce, by one or more arbitrators named pursuant to
these Rules. The place of arbitration shall be Paris and the language of
arbitration shall be French.
ARTICLE 22 — POWER OF ATTORNEY
Power of attorney is given to the bearer of a copy or excerpt of this agreement
in order to carry out all formalities, and in particular in order to cause this
agreement to be filed with the National offices of the relevant countries.
ARTICLE 23 — NOTIFICATION OF THE IL-13 AGREEMENT — REGISTRATION
Notice of the IL-13 License Agreement and the Amendment to the IL-13 License
Agreement shall be given by IDM to the Bureau of Transfers of the National
Institute of Industrial Property (Institut National de la Propriété
Industrielle) and/or listed with the relevant foreign Industrial Property
offices, and the Parties agree here and now to sign all documents,
power-of-attorney and other powers necessary to the implementation and
registration of the IL-13 License Agreement and/or of the Amendment to the IL-13
License Agreement in order to make them opposable to Third Parties in all
countries.
In the event this IL-13 Agreement is registered, all costs and fees relative to
such formality shall be paid by IDM.
Executed in Paris on November 30, 2001, in two (2) originals.

                  IDM       SANOFI-SYNTHELABO
 
                /s/ Jean-Loup Romet-Lemonne       /s/ Jean-Claude Leroy        
 
By:
  Jean-Loup Romet-Lemonne       By:   Jean-Claude Leroy
 
  President           Senior Vice President, Strategy and Business Development
 
                /s/ Bernard Brigonnet       /s/ José Ferrer          
By:
  Bernard Brigonnet       By:   José Ferrer
 
  Managing Director           Director Legal Affairs Operations

22

--------------------------------------------------------------------------------

 

LIST OF ANNEXES

     
ANNEX 1.10. :
  Detailed description of the IL-13 patents
 
   
ANNEX 1.13. :
  List of IDM shareholders as at the 1999 signature date
 
   
ANNEX 1.25. :
  IL-13 detailed description.
 
   
ANNEX 1.35. :
  List of il-13 development programs in effect as of the execution date of the
IL-13 agreement.
 
   
ANNEX 6.2.2. :
  IL-13 License Agreement
 
   
ANNEX 6.3.2. :
  Amendment No. 1 to IL-13 License Agreement
 
   
ANNEX 7. :
  Exercise conditions for BSA1 and BSA 2 warrants
 
   
ANNEX 10. :
  Reservations relative to the guarantees on the IL-13 intellectual property

23

--------------------------------------------------------------------------------

 

ANNEX 1.10 :
Detailed description of ii-13 patents
[...***...]
[...***...]

         
 
  *   Confidential Treatment Requested
under 17 C.F.R. §§ 200.80(b)(4) and
 
      240.24b-2(b)(1)

24

--------------------------------------------------------------------------------

 

[...***...]

         
 
  *   Confidential Treatment Requested
under 17 C.F.R. §§ 200.80 (b)(4) and
 
      240.24b-2(b)(1)

25

--------------------------------------------------------------------------------

 

ANNEX 1.13. :
list of idm shareholders as at the signature date of the 1999 agreement
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]

         
 
  *   Confidential Treatment Requested
under 17 C.F.R. §§ 200.80 (b)(4) and
 
      240.24b-2(b)(1)

26

--------------------------------------------------------------------------------

 

[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]

         
 
  *   Confidential Treatment Requested
under 17 C.F.R. §§ 200.80 (b) (4) and
 
      240.24b-2(b)(1)

27

--------------------------------------------------------------------------------

 

[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]
[...***...]

         
 
  *   Confidential Treatment Requested
under 17 C.F.R. §§ 200.80(b)(4) and
 
      240.24b-2(b)(1)

28

--------------------------------------------------------------------------------

 

[...***...]
[...***...]
[...***...]

         
 
  *   Confidential Treatment Requested
under 17 C.F.R. §§ 200.80(b)(4) and
 
      240.24b-2(b)(1)

29

--------------------------------------------------------------------------------

 

ANNEX 1.25. :
IL-13 detailed description
IL-13 is the exclusive designation of [...***...].
IL-13 also designates all [...***...].

         
 
  *   Confidential Treatment Requested
under 17 C.F.R. §§ 200.80(b)(4) and
 
      240.24b-2(b)(1)

30

--------------------------------------------------------------------------------

 

ANNEX 1.35. :
List of IL-13 Development Programs in effect on the execution date of the IL-13
Agreement
[...***...]

     
[...***...]
   
 
  [...***...]
 
  [...***...]
 
  [...***...]
 
   
[...***...]
   
 
       [...***...]
 
       [...***...]
 
       [...***...]
 
       [...***...]
 
   
[...***...]
   
 
       [...***...]
 
       [...***...]
 
       [...***...]
 
       [...***...]
 
   
[...***...]
   
 
  [...***...]
 
  [...***...]
 
   
[...***...]
   
 
  [...***...]
 
  [...***...]
 
   
[...***...]
   
 
  [...***...]
 
  [...***...]
 
   
[...***...]
   
 
  [...***...]
 
  [...***...]

         
 
  *   Confidential Treatment Requested
under 17 C.F.R. §§ 200.80(b)(4) and
 
      240.24b-2(b)(1)

31

--------------------------------------------------------------------------------

 

     
          [...***...]
   
 
  [...***...]
 
  [...***...]
 
   
          [...***...]
   
 
  [...***...]
 
  [...***...]

[...***...]
[...***...]

     
[...***...]
   
[...***...]
   
[...***...]
   
 
   
[...***...]
   
 
   
[...***...]
   
 
   
          [...***...]
   
 
       [...***...]
 
       [...***...]
 
       [...***...]
 
       [...***...]
 
   
          [...***...]
   
 
       [...***...]
 
       [...***...]
 
       [...***...]
 
       [...***...]

         
 
  *   Confidential Treatment Requested
under 17 C.F.R. §§ 200.80(b)(4) and
 
      240.24b-2(b)(1)

32

--------------------------------------------------------------------------------

 

     
     [...***...]
   
 
  [...***...]
 
  [...***...]
 
  [...***...]
 
  [...***...]
 
   
[...***...]
   
 
  [...***...]
 
  [...***...]
 
  [...***...]
 
  [...***...]
 
   
[...***...]
   
 
  [...***...]
 
  [...***...]
 
  [...***...]
 
  [...***...]
 
   
[...***...]
   
 
  [...***...]
 
  [...***...]
 
  [...***...]
 
  [...***...]

         
 
  *   Confidential Treatment Requested
under 17 C.F.R. §§ 200.80(b)(4) and
 
      240.24b-2(b)(1)

33

--------------------------------------------------------------------------------

 

     
                    [...***...]
   
 
  [...***...]
 
  [...***...]
 
  [...***...]
 
  [...***...]
 
   
          [...***...]
   
 
  [...***...]
 
  [...***...]
 
  [...***...]
 
  [...***...]
 
   
[...***...]
   
 
   
          [...***...]
   
 
  [...***...]
 
  [...***...]
 
  [...***...]
 
  [...***...]
 
   
          [...***...]
   
 
  [...***...]
 
  [...***...]
 
  [...***...]
 
  [...***...]

         
 
  *   Confidential Treatment Requested
under 17 C.F.R. §§ 200.80(b)(4) and
 
      240.24b-2(b)(1)

34

--------------------------------------------------------------------------------

 

ANNEX 6.2.2 :
IL-13 Intellectual Property License Agreement
[Obsolete — replaced by the Amended and Restated IL-13 license agreement entered
into on
August 12, 2005 following early exercise by Sanofi-Aventis of its BSA1 and BSA2
warrants]

35

--------------------------------------------------------------------------------

 

Annex 6.3.2.:
Amendment 1 to the IL-13 Intellectual Property License Agreement
[Obsolete — replaced by the Amended and Restated IL-13 license agreement entered
into on
August 12, 2005 following early exercise by Sanofi-Aventis of its BSA1 and BSA2
warrants]

36

--------------------------------------------------------------------------------

 

Annex 7. :
Terms and Conditions for the exercise of the BSA 1 and BSA 2 warrants
[Obsolete since BSA1 and BSA2 warrants have been exercised]

37

--------------------------------------------------------------------------------

 

Annex 10 :
Reservations relative to the guarantees on the IL-13 Intellectual Property
The Parties recognize that IDM carried out, prior to signing the 1999 Agreement,
an audit of the IL-13 Intellectual Property rights.
This audit was conducted through [...***...], which prepared a specific report
dated April 28, 1999 (herienafter, the « Report ») sent to IDM and a copy of
which was transmitted to SANOFI-SYNTHELABO.
The Report is deemed to be an integral part of this IL-13 Agreement.
It is understood by the Parties that the guarantees defined in Article 10 of
this IL-13 Agreement are extended subject to the items set forth in the Report,
in particular as regards the [...***...] patents referred to therein.
More generally, it is understood that in no event may IDM hold SANOFI-
SYNTHELABO liable, on any basis whatsoever, for facts as to which
SANOFI-SYNTHELABO can demonstrate that IDM had knowledge on the date of
signature of the 1999 Agreement, either as a result of the completion of the
above-mentioned audit, or by any other way.

         
 
  *   Confidential Treatment Requested
under 17 C.F.R. §§ 200.80(b)(4) and
 
      240.24b-2(b)(1)

38